The Challenge

Although immunotherapy has revolutionised cancer treatment, several challenges remain:

  • Many patients do not respond to, or become resistant to, immunotherapy
  • Some tumour types are non-responsive to immunotherapy (cold)
  • Efficacy can be limited by safety and toxicity

There is scope to increase the efficacy, applicability, and/or safety of existing immunotherapies.

Modulating IL-21 Activity

Previous studies have shown that modulating IL-21 activity can enhance immunotherapy.


Pio Therapeutics is developing a first-in-class agonistic antibody to IL-21.

We have generated a selective agonistic antibody with the potential to amplify the effect of IL-21.